National Cancer Screening and Early Diagnosis Guidelines

Objectives

Kenya’s 2024 National Cancer Screening and Early Diagnosis Guidelines provide a national framework to standardise cancer prevention, screening, early diagnosis, referral and linked treatment across public, private and faith-based healthcare services. They support the National Cancer Control Strategy 2023–2027 and aim to reduce preventable cancer burden, late presentation, mortality and health inequalities through evidence-based, patient-centred care.[1][2][3]

• Strengthen prevention, early detection, diagnosis, treatment linkage, survivorship and palliative care across the cancer continuum.[1][4]
• Prioritise population-level screening for cervical, breast and colorectal cancers; targeted screening for prostate, oral cancer and retinoblastoma; and early diagnosis for childhood, oesophageal, lung and other priority cancers.[5][3]
• Improve early diagnosis of symptomatic people by increasing awareness of warning signs, enabling prompt clinical assessment, and connecting patients to diagnostic and treatment services at the earliest possible stage.[4][6]
• Advance cervical cancer elimination by seeking to screen 70% of women with a high-performance human papillomavirus test and treat 90% of women with pre-cancer or confirmed cancer by 2030.[7]
• Expand risk-appropriate prevention and early detection, recognising that screening is appropriate only for selected cancers whereas early diagnosis is relevant across cancer types.[4][6]
• Promote equitable access, including services and communication adapted for women living with disabilities and patient-centred decisions that do not deny eligible people access to screening.[3][8]

Implementation

The guidelines use a health-system-based, risk-stratified delivery model that links community awareness, screening or symptom recognition, diagnostic confirmation, referral, treatment and follow-up. Implementation depends on national and county leadership, capable facilities and workforces, functioning referral pathways, quality assurance, information systems, and collaboration among government, professional bodies, academia, facilities, civil society, survivors, development partners and the private sector.[1][4][3]

• Apply evidence-based screening modalities according to cancer type and risk: primary human papillomavirus testing for cervical cancer; clinical breast examination and mammography according to risk and age; faecal immunochemical testing or guaiac-based faecal occult blood testing followed by colonoscopy for colorectal cancer; quantitative prostate-specific antigen testing through shared decision-making; and visual examination for oral cancer in at-risk groups.[5][9][10][11][12]
• Use cervical screen-and-treat or screen-triage-and-treat pathways, with visual inspection with acetic acid, cytology, genotyping or colposcopy as appropriate for triage, and provide ablative or excisional treatment or referral for eligible women.[13][14][15]
• Integrate cervical screening with HIV services, including differentiated screening intervals, self-collection where suitable, peer navigation and alignment with routine HIV care to reduce loss to follow-up.[16][15]
• Deliver services across levels of care, with community and primary-care workers supporting awareness, mobilisation, basic assessment, sample collection and referral, while higher-level facilities provide imaging, endoscopy, pathology, specialist diagnosis, treatment and complex care.[17][18][19][20]
• Establish coordinated referral and counter-referral arrangements, including directories of diagnostic facilities, standard referral information, specimen transport, patient navigation, scheduled follow-up and communication between facilities.[21][20][22]
• Build workforce and facility readiness through training, mentorship, supervision, appropriate equipment, supply and sample-management systems, validated assays, diagnostic capacity, evidence-based protocols, and quality-control and quality-assurance processes.[4][23][24][25]
• Assess disease burden, target-population suitability, community and provider acceptability, test performance, diagnostic and treatment capacity, affordability, available funds and cost-effectiveness before establishing or expanding screening programmes.[4]
• Use health information and patient-tracking systems to link positive screening results to care, document diagnosis and staging, monitor follow-up, and reduce missed referrals and loss to follow-up.[26][20][22]
• Monitor cervical programme performance through screening coverage, test positivity, treatment rates, county and facility rates, target-age coverage and data use, including quarterly scorecard review.[24]
• Measure cancer-specific quality and outcome indicators where specified, including colorectal colonoscopy quality measures, oral-cancer screening and early-stage diagnosis indicators, and referral rates, waiting times and patient outcomes for colorectal services.[18][21][27]

Monitoring & Evaluation

The guidelines combine programme monitoring, clinical follow-up, service-quality assurance and referral tracking across cancer screening and early-diagnosis services. The most developed measurement framework concerns cervical cancer, while oral cancer and colorectal endoscopy also have explicit indicators; several other cancer sections provide clinical follow-up schedules but do not define programme-level reporting or accountability arrangements.[4][24][27][18]

• Track cervical cancer progress against the World Health Organization 2030 targets of screening 70% of women with a high-performance human papillomavirus test and treating 90% of women with pre-cancer or confirmed cancer.[7]
• Monitor cervical screening coverage, test distribution and positivity, treatment following a positive result, linkage to care, county and facility screening rates, target-age-group coverage, pre-cancer treatment rates and facility data consumption.[7][24]
• Review cervical programme performance monthly and use a scorecard for quarterly review of target achievement and positivity among first-time screened women aged 25 to 49 years.[24]
• Use Kenya Health Information System data and participant-tracking systems to measure screening and treatment outcomes, including fail-safe linkage of people with positive screening results to treatment. In 2024, screening coverage among women aged 25 to 49 years was 30.3%, and 33% of women with a positive screening test received treatment.[7][26]
• Maintain quality control, quality assurance, provider training and supervision for cervical screening, particularly visual inspection with acetic acid services, and document examination findings.[23]
• Schedule post-treatment cervical follow-up at one year, preferably using human papillomavirus testing, with further evaluation or possible re-treatment after a positive result and continued long-term surveillance where lesions may persist or recur.[8][28]
• Follow women living with HIV annually for life after treatment and integrate follow-up with other HIV services; continue lifelong screening for women with previous high-grade lesions or cervical cancer.[15]
• Measure oral-cancer programme inputs, coverage and outcomes, including trained workers, people screened, demographic characteristics, risk factors, equipped facilities, referrals, early-stage diagnosis, incidence and five-year survival.[27]
• Monitor colorectal referral rates, waiting times and patient outcomes, then regularly update referral systems using feedback and performance data.[21]
• Measure colonoscopy quality through caecal intubation rate, adenoma detection rate and withdrawal time, with targets of at least 95%, at least 25% and at least six minutes respectively.[18]
• Maintain medical records documenting diagnosis, staging, management plans and follow-up status, supported by counter-referrals, longitudinal tracking, patient navigators, mobile-phone contact, line lists, tumour boards and integrated electronic medical records.[20][22]
• Establish a cancer registry, routine reporting, site visits, staged evaluations and feedback mechanisms for oesophageal cancer early-diagnosis activities.[29]
• Establish data-collection and monitoring systems for prostate screening, use findings to assess effectiveness and adjust the programme, and address informed consent and incidental findings.[30]
• Apply clinical monitoring schedules for retinoblastoma according to genetic status, family history and age, with urgent referral for abnormal or absent red reflexes.[31][32]

Many sections do not specify reporting frequency, named reporting institutions, surveillance architecture, audit arrangements or formal accountability mechanisms. This limitation applies particularly to breast, lung, childhood, colorectal risk-stratification, retinoblastoma and broad early-diagnosis guidance, except where clinical follow-up, referral or service-quality processes are described.[33][34][35][36][37][6]

Costing & Financing

The guidelines provide limited quantified financing information. They emphasise affordability, cost-effectiveness, equipment, supply chains, trained personnel and diagnostic capacity as conditions for feasible screening, but do not set a Kenya-specific cancer-screening budget, allocation, funding gap or resource-mobilisation target.[4][24]

• Consider affordability, cost-effectiveness, funds, equipment, trained personnel, diagnostic capacity, treatment availability and follow-up capacity before establishing screening programmes.[4]
• Recognise global direct and indirect costs of cancer prevention and treatment as expected to exceed 25.2 trillion US dollars during 2020 to 2050; a separate cited estimate places the global cost of cancer at 25 trillion US dollars over the next 30 years. Neither estimate is a Kenya-specific programme budget.[2][26]
• Use financial and technical assistance provided for guideline development by the World Health Organization, FIND Diagnostics, Roche, the United States Agency for International Development and the Clinton Health Access Initiative.[5]
• Account for shortages of human papillomavirus testing equipment and reagents as barriers to scaling up primary human papillomavirus screening.[7]
• Assess costs and benefits of human papillomavirus tests, equipment, supplies, maintenance, distribution conditions and operational requirements when selecting cervical screening technologies.[24]
• Recognise that visual inspection with acetic acid uses locally sourced supplies, does not require laboratory services and is relatively inexpensive, while self-collection may reduce health-system costs and healthcare burdens.[14][23]
• Recognise thermal ablation as a low-cost treatment comparable with cryotherapy, while accounting for electricity requirements and limited refrigerant gas availability for cryotherapy.[38]
• Avoid routine co-testing with human papillomavirus and Pap smear, which is characterised as not cost-effective and no more effective than high-risk human papillomavirus testing alone for predicting precancerous or invasive lesions.[13]
• Prioritise faecal immunochemical testing and guaiac-based faecal occult blood testing as cost-effective colorectal screening options; annual faecal immunochemical testing is described as cost-effective or cost-saving compared with colonoscopy every 10 years.[39][40]
• Recognise guaiac-based faecal occult blood testing as low cost, while stool DNA testing and colonoscopy are described as higher-cost options.[39][40]
• Address infrastructure costs and logistical constraints for mammography roll-out, which is described as expensive and challenging in low- and middle-income settings.[33]
• Provide adequate funding for oral and nasopharyngeal cancer screening, diagnostics, research and development, and procurement of diagnostic equipment, consumables, toluidine and fluorescence reagents.[41]
• Use universal health coverage, the Social Health Insurance Fund and the chronic-diseases fund as potential mechanisms to reduce financial and geographic barriers, including direct and indirect out-of-pocket treatment costs.[22]
• Recognise early diagnosis as more cost-effective and less costly than prevailing late-stage diagnosis and treatment, although no economic model or monetary estimate is provided.[42][6]

No monetary budget, unit-cost schedule, financing allocation or quantified funding gap is specified for cervical, breast, colorectal, prostate, oral, retinoblastoma, childhood, oesophageal or lung cancer services in the supplied material.[16][43][44][11][45][46][36][37]